Y-l Wu - Publications

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 07, 2026

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial.

Journal: ESMO open

Published: May 17, 2023

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 30, 2022

Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 24, 2020

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 01, 2019

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 17, 2018

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 13, 2017

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 07, 2016

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 20, 2015

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 05, 2014

Enhanced MC3T3-E1 preosteoblast response and bone formation on the addition of nano-needle and nano-porous features to microtopographical titanium surfaces.

Journal: Biomedical materials (Bristol, England)

Published: June 20, 2014

Reply to 'Concern on quality-of-life analysis in the OPTIMAL study' by Couraud et al.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 24, 2013